Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...

By Maggie Fick LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an ...

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...

Explore the fierce competition between Novo Nordisk and Pfizer as they vie for Metsera amidst a booming obesity drug market.

Analysts say Pfizer could use its strong connections within the Trump administration to bolster its case, with CEO Albert ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the ...

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...